Predictors of Plasma Human Immunodeficiency Virus Type 1 RNA Control after Discontinuation of Highly Active Antiretroviral Therapy Initiated at Acute Infection Combined with Structured Treatment Interruptions and Immune-Based Therapies

Journal of Infectious Diseases

Volumn 188, Issue 10, 2003, Pages 1426-1432

  Lafeuillade, A ^a   Poggi, C ^b   Hittinger, G ^a   Counillon, E ^b   Emilie, D ^c  

^a Hopital Chalucet Toulon   (France)

^b GENERAL HOSPITAL   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; HYDROXYUREA; INTERLEUKIN 2; LAMIVUDINE; NELFINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BIOLOGICAL PARAMETER ASSESSMENT; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CORRELATION ANALYSIS; FEMALE; FUNCTIONAL ASSESSMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOTHERAPY; LACTIC ACIDOSIS; LEUKOPENIA; LIPOATROPHY; LYMPH NODE; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MALE; MONONUCLEAR CELL; MULTIVARIATE ANALYSIS; NEURITIS; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; SIDE EFFECT; VIREMIA; VIRUS INFECTION; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; HYDROXYUREA; INTERLEUKIN-2; MALE; MULTIVARIATE ANALYSIS; NUCLEIC ACID SYNTHESIS INHIBITORS; PILOT PROJECTS; PROPORTIONAL HAZARDS MODELS; PROVIRUSES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIREMIA; VIRUS REPLICATION;

EID: 0346850793     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/379251     Document Type: Article

References (38)

1. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33-9.
2. Berrey MM, Schacker T, Collier AC, et al. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 2001; 183:1466-75.
3. Stekler J, Collier A. Treatment of primary HIV. Curr Infect Dis Rep 2002; 4:81-7.
4. Miller J, Carr A, Smith D, et al. Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS 2000; 14:2406-7.
5. Goujard C, Boufassa F, Deveau C, Laskri D, Meyer L. Incidence of clinical lipodytrophy in HIV-1-infected patients treated during primary infection. AIDS 2001; 15:282-4.
6. Narciso P, Tozzi V, D'Offizi G, et al. Metabolic and morphologic disorders in patients treated with highly active antiretroviral therapy since primary HIV infection. Ann NY Acad Sci 2001; 946:214-22.
7. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society - USA Panel. JAMA 2002; 288:222-35 [erratum: JAMA 2003; 11:32].
8. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-6.
9. + T lymphocytes. Proc Natl Acad Sci USA 2000; 97:3382-7.
10. Girard PM, Schneider V, Dehée A, et al. Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection. AIDS 2001; 15:275-7.
11. Fidler S, Oxenius A, Brady M, et al. Virological and immunological effects of short-course antiretroviral therapy in primary HIV infection. AIDS 2002; 16:2049-54.
12. Lori F, Lewis MG, Xu J, et al. Control of SIV rebound through structured treatment interruptions during early infection. Science 2000; 290:1591-3.
13. Dybul M. Structured treatment interruption: approaches and risk. Curr Infect Dis Rep 2002; 4:175-80.
14. Miro JM, Plana M, Garcia F, et al. Structured treatment interruptions (STI) in patients receiving HAART within 90 days after onset of primary HIV-1 infection (PHI) symptoms: spontaneous control of viremia in only one third of cases after four cycles off therapy [abstract ThOrB1437]. In: Program and abstracts of the 14th International AIDS Conference (Barcelona). Stockholm: International AIDS Society, 2002:203.
15. Schockmel GA, Yerly S, Perrin L. Detection of low HIV-1 RNA levels in plasma. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:179-83.
16. Lafeuillade A, Poggi C, Profizi N, Tamalet C, Costes O. Human immunodeficiency virus type 1 dynamics in lymph nodes compared with plasma. J Infect Dis 1996; 174:404-7.
17. Yerly S, Rutschmann OT, Opravil M, Marchal F, Hirschel B, Perrin L. Cell-associated HIV-1 RNA in blood as indicator of viral load in lymph nodes. J Infect Dis 1999; 180:850-3.
18. Christopherson C, Kidane Y, Conway B, Krowka J, Sheppard H, Kwok S. PCR-based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells. J Clin Microbiol 2000; 38:630-4.
19. Burgard M, Izopet J, Dumon B, et al. HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment. AIDS Res Hum Retroviruses 2000; 16:1939-47.
20. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-6.
21. Hel Z, Venzon D, Poudyal M, et al. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nat Med 2000; 6:1140-6.
22. Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999; 340:1683-4.
23. Markowitz M, Jin X, Hurley A, et al. Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002; 186:634-43.
24. Kelleher AD, Roggensack M, Emery S, Carr A, French MA, Cooper DA. Effects of IL-2 therapy in asymptomatic HIV-infected individuals on proliferative responses to mitogens, recall antigens and HIV-related antigens. Clin Exp Immunol 1998; 113:85-91.
25. Kulkosky J, Pomerantz RJ. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy. Clin Infect Dis 2002; 35:1520-6.
26. Garcia F, Plana M, Arnedo M, et al. A cytostatic drug improves control of HIV-1 replication during structured treatment interruptions: a randomized study. AIDS 2003; 17:43-51.
27. Lafeuillade A, Poggi C, Tamalet C, et al. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J Infect Dis 1997; 175:1051-5.
28. Van Leeuven R, Katlama C, Murphy RL, et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1 infected patients. AIDS 2003; 17:987-99.
29. Ruiz L, Van Lunzen J, Arno A, et al. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 1999; 13:F1-8.
30. Lafeuillade A, Poggi C, Chadapaud S, Hittinger G, Khiri A, Halfon P. Impact of immune interventions on proviral HIV-1 DNA decay in patients receiving highly active antiretroviral therapy. HIV Med 2001; 2:189-94.
31. Dornadula G, Nunnari G, Vanella M, et al. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologie and immunologic subgroups. J Infect Dis 2001; 183:1682-7.
32. Tierney C, Lathey JL, Christopherson C, et al. Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy. J Infect Dis 2003; 187:144-8.
33. Yerly S, Perneger TV, Vora S, Hirschel B, Perrin L. Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS 2000; 14:2805-12.
34. Karlsson AC, Birk M, Lindback S, Gaines H, Mittler JE, Sonneborg A. Initiation of therapy during primary HIV type 1 infection results in a continuous decay of proviral DNA and a highly restricted viral evolution. AIDS Res Hum Retroviruses 2001; 17:409-16.
35. Schacker T, Little S, Connick E, et al. Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis 2001; 183:555-62.
36. Persaud D, Zhou Y, Siliciano JM, Siliciano RF. Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol 2003; 77:1659-65.
37. Kostrikis LG, Touloumi G, Karanocolas R, et al. Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol 2002; 76:10099-108.
38. + T cells and HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral replication. J Virol 2002; 76:5925-36.